Want to see IN:ENTERO full AI Analyst Report?
ENTERO Stock Chart & Stats
₹1230.80
₹43.80(3.56%)
At close: 4:00 PM EDT
₹1230.80
₹43.80(3.56%)
Day’s Range― - ―
52-Week Range₹944.00 - ₹1,919.25
Previous CloseN/A
Volume165.84K
Average Volume (3M)21.43K
Market Cap
₹63.92B
Enterprise Value₹58.72B
Total Cash (Recent Filing)₹2.96B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)51.0
Beta0.60
Next Earnings
Nov 04, 2026EPS Estimate
11.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)28.82
Shares Outstanding43,523,070
10 Day Avg. Volume9,058
30 Day Avg. Volume21,431
Financial Highlights & Ratios
PEG Ratio2.22
Price to Book (P/B)3.22
Price to Sales (P/S)0.82
P/FCF Ratio3.05K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,800.00Price Target Upside46.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)40.88
Revenue Forecast (FY)₹82.69B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid expansion in revenue shows that Entero is scaling its healthcare distribution network and increasing volumes across pharmacies, hospitals, and institutional customers. Continued growth provides a broader operating base and can support stronger earnings if the company preserves customer reach and execution quality.
Profitability TurnaroundThe shift from several years of losses to positive FY2026 net income is a meaningful improvement in the business model’s earnings capacity. Although profitability remains modest, the turnaround indicates that higher scale and operating execution are translating into positive bottom-line performance.
Equity-Supported Balance SheetA sizeable equity base relative to debt provides Entero with a more substantial financial foundation for operating as a healthcare distributor. Debt-to-equity around 0.40 indicates that equity remains the larger funding source, supporting resilience and room to manage ongoing business requirements.
Bears Say
Thin And Compressing MarginsLow and declining margins leave limited room to absorb changes in product mix, pricing, or operating costs. Gross-margin compression from FY2024 to FY2026 also suggests that revenue growth is not fully translating into improved economics, making sustainable profit expansion more difficult.
Weak Cash ConversionCash generation has lagged reported earnings for an extended period, with operating cash flow negative through FY2025 and FY2026 free cash flow essentially break-even. This weak conversion can constrain internal funding, reduce financial flexibility, and make growth more dependent on working-capital management.
Rising Leverage And Modest ReturnsHigher leverage increases the financial obligations attached to a business whose cash generation remains weak. At the same time, the latest available return on equity is modest, so the larger capital base has not yet produced a strong return profile that would clearly offset the added balance-sheet risk.
Entero Healthcare Solutions Limited News
ENTERO FAQ
What was Entero Healthcare Solutions Limited’s price range in the past 12 months?
Entero Healthcare Solutions Limited lowest stock price was ₹944.00 and its highest was ₹1919.25 in the past 12 months.
What is Entero Healthcare Solutions Limited’s market cap?
Entero Healthcare Solutions Limited’s market cap is ₹63.92B.
When is Entero Healthcare Solutions Limited’s upcoming earnings report date?
Entero Healthcare Solutions Limited’s upcoming earnings report date is Nov 04, 2026 which is in 9 days.
How were Entero Healthcare Solutions Limited’s earnings last quarter?
Entero Healthcare Solutions Limited released its earnings results on Aug 07, 2026. The company reported ₹8.8 earnings per share for the quarter, beating the consensus estimate of ₹6.8 by ₹2.
Is Entero Healthcare Solutions Limited overvalued?
According to Wall Street analysts Entero Healthcare Solutions Limited’s price is currently Undervalued.
Does Entero Healthcare Solutions Limited pay dividends?
Entero Healthcare Solutions Limited does not currently pay dividends.
What is Entero Healthcare Solutions Limited’s EPS estimate?
Entero Healthcare Solutions Limited’s EPS estimate is 11.8.
How many shares outstanding does Entero Healthcare Solutions Limited have?
Entero Healthcare Solutions Limited has 43,523,070 shares outstanding.
What happened to Entero Healthcare Solutions Limited’s price movement after its last earnings report?
Entero Healthcare Solutions Limited reported an EPS of ₹8.8 in its last earnings report, beating expectations of ₹6.8. Following the earnings report the stock price went up 0.314%.
Which hedge fund is a major shareholder of Entero Healthcare Solutions Limited?
Currently, no hedge funds are holding shares in IN:ENTERO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Entero Healthcare Solutions Limited
Established in 2018 and headquartered in Mumbai, India, Entero Healthcare Solutions Limited functions as a key distributor within the Indian healthcare sector. The company specializes in supplying a diverse range of medical and health-related products, including pharmaceuticals, surgical instruments, medical equipment, over-the-counter remedies, nutritional supplements, and vaccines. Its extensive client base spans retail pharmacies, hospitals, nursing homes, and various healthcare clinics throughout the country.
ENTERO Stock 12 Month Forecast
Average Price Target
₹1,800.00
▲(46.25% Upside)
Technical Analysis
Artemis Medicare Services Ltd.
―
Bliss Gvs Pharma Limited
―
Orchid Pharma Limited
―
RPG Life Sciences Limited
―
Unichem Laboratories Limited
―